Journal
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume 83, Issue 2, Pages 369-374Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2020.01.002
Keywords
immunosuppressants; perioperative management; postoperative treatment; prophylaxis; pyoderma gangrenosum; surgery
Categories
Ask authors/readers for more resources
Pyoderma gangrenosum (PG) classically presents with an acute inflammatory stage, characterized by rapid evolution of painful ulcerations. The pathergy associated with PG lesions complicates disease management. Although PG is commonly treated with immunosuppression, some patients have refractory noninflammatory ulcers. In this subpopulation, there are case reports of successful surgical treatment. However, there is no consensus on optimal perioperative treatment for patients with PG undergoing surgery of any kind, PG related or otherwise. Therefore, we conducted a comprehensive literature review describing perioperative management practices and risk factors that may predict response to surgical intervention. We identified 126 cases of surgical intervention in patients with active PG; among these, only 16.7% experienced postoperative disease progression. No perioperative treatments or clinical risk factors were identified as statistically significant predictors of disease recurrence. Although limited by case series design and publication bias, this study is a valuable means of hypothesis generation for this rare condition.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available